Seeking Alpha
08 Jun 2026, 06:48 UTC · 7h ago
Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities
Search tags
Seeking Alpha
08 Jun 2026, 06:48 UTC · 7h ago
Search tags
Story key points
3 claims · impact-rated
EYLEA HD U.S. sales increased by 52% in Q1 2026. — Significant revenue growth in a core product demonstrates market share retention despite competitive pressures.
+0.60Pending regulatory decisions for EYLEA HD and CEMDISIRAN act as near-term catalysts. — FDA decisions create binary events that can trigger immediate price volatility based on approval or rejection.
+0.40Dupixent continues to show strong growth. — Sustained growth in a blockbuster drug provides a stable revenue floor and supports overall valuation.
+0.30Ticker attribution
Model heads
Continue reading
6 related stories
Strong growth in DUPIXENT and EYLEA HD sales, combined with a promising pipeline and a 'Buy' rating.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
8 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Schaeffers Research
32m ago
Seeking Alpha
4h ago
